1) Antithrombin Cambridge II
抗凝血酶剑桥II
2) antithrombin
[,ænti'θrɔmbin]
抗凝血酶
1.
Postoperative antithrombin levels and adverse outcome in cardiac operations;
体外循环心脏术后抗凝血酶活性与手术不良结果的相关性
2.
Clinical significance of plasma antithrombin and fibrinolysin in asphyxiated newborns;
抗凝血酶和纤溶功能的变化在窒息新生儿中的临床意义
3.
Significance of the Changes of Plasma vWF,D-dimer and Antithrombin Levels in Patients with Hematological Malignancy;
血液肿瘤患者中血管性血友病因子、D二聚体、抗凝血酶检测的意义
3) Antithrombin Ⅲ
抗凝血酶Ⅲ
1.
Correlative study between the changes of antithrombin Ⅲ activity & D-dimer level and sequential organ failure assessment score in the patients with sepsis;
脓毒症患者血浆抗凝血酶Ⅲ及D-二聚体与SOFA评分的相关性研究
2.
Screening of Antithrombin Ⅲ(AT-Ⅲ) with High Bioactivity by DNA Shuffling in P.pastoris;
利用DNA改组筛选高活性抗凝血酶Ⅲ
3.
Expression of Soluble Recombinant Human Antithrombin Ⅲ(AT-Ⅲ) inP.pastoris;
人抗凝血酶Ⅲ(AT-Ⅲ)在毕赤酵母中可溶性表达
4) Antithrombin-Ⅲ
抗凝血酶Ⅲ
1.
Immunoresonance Scautering Spectral Assay for the Determination of Antithrombin-Ⅲ;
抗凝血酶Ⅲ的免疫共振散射光谱分析
2.
Antithrombin-Ⅲ concentrations in lung cancer patients were significantly lower(73.
目的对119例肺癌患者D二聚体(D-dimer)和抗凝血酶Ⅲ(antithrombinⅢ,AT-Ⅲ)活性进行检测,以探讨上述指标与肺癌的关系及意义。
5) AT-Ⅲ
抗凝血酶Ⅲ
1.
The plasmea lever of vWF,GMP-140,TF,FⅡα,AT-Ⅲ and D-Dimer of the subjects were mea.
方法:21例原发性肝癌经肝动脉插管栓塞化疗(TACE)患者分别于插管前(全身)、注射栓塞剂前(局部)、注射栓塞剂后30分钟(局部)、注射栓塞后3小时(全身)以及术后24小时(全身)5个时段,测定血浆TF(组织因子)、vWF(血管性血友病因子)、GMP-140(血浆α-颗粒膜蛋白)、FⅡα(凝血酶)、AT-Ⅲ(抗凝血酶Ⅲ)和D-Dimer(D-二聚体)含量;12名健康志愿者组成正常对照组,同时测定上述指标,对结果进行统计学分析。
2.
After feeding drugs through stomach for one month,tail thrombus models were established by carrageenan in rats except the normal control group,The black tail length,the activ of AT-Ⅲ,the content of D-dimer,the c.
灌胃时间1个月,除正常对照组外,其他3组均用角叉菜胶构建尾部血栓模型,观察不同时间的黑尾长度,抽血查抗凝血酶Ⅲ(AT-Ⅲ)活性、D-二聚体含量、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)、肿瘤坏死因子α(TNF-α)的含量。
3.
In the review, The dose, caution and adatption of fresh platets, fresh frez en platets, fresh plasma, fresh frozen plasma, prothrombin complex concentrates and fibinogen contentrates as wella as AT-Ⅲ and protein C as anticoagulatory fa ctors are described.
本文对DIC时应用新鲜血小板、新鲜冰冻血小板、新鲜血浆、新鲜冰冻血浆等补充凝血因子、血小板的适应证、应用剂量及注意事项作了总结,并对血液中的抗凝成分抗凝血酶Ⅲ、蛋白C在DIC中的应用现状进行了概述。
6) AntithrombinⅢ
抗凝血酶Ⅲ
1.
The effect of antithrombinⅢ on endotoxininduced multiple organ dysfunction syndrome;
抗凝血酶Ⅲ防治内毒素血症致多器官功能不全的实验研究
补充资料：抗凝血酶Ⅲ
抗凝血酶Ⅲ
血浆中一种抗丝氨酸蛋白酶。是人体内一类较重要的生理性抗凝物质。凝血因子Ⅱa、Ⅶ、Ⅸa、Ⅹa的活化中心均含有丝氨酸残基，都属于丝氨酸蛋白酶，ATⅢ分子上的精氨酸残基，可以与这些酶活性中心的丝氨酸残基结合，这样就"封闭"了这些酶的活性中心而使之失活。在血液中，每一分子ATⅢ，可以与一分子的凝血酶结合形成复合物，从而使凝血酶失活。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条